CD38 and Miyoshi myopathy: Daratumumab, a fully human IgG1 antibody, eliminates MM cells expressing CD38 through various direct mechanisms: antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell mediated-phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and induction of programmed cell death (apoptosis) in the presence of a cross-linking antibody [6,7,8] as well as immunomodulatory mechanisms [9,10].